Russell Investments Group Ltd. Sells 5,279 Shares of Repligen Co. (NASDAQ:RGEN)

Russell Investments Group Ltd. lowered its stake in shares of Repligen Co. (NASDAQ:RGEN) by 13.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 33,388 shares of the biotechnology company’s stock after selling 5,279 shares during the quarter. Russell Investments Group Ltd.’s holdings in Repligen were worth $6,013,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Signaturefd LLC raised its holdings in shares of Repligen by 44.1% in the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 86 shares during the last quarter. Milestone Investment Advisors LLC purchased a new stake in Repligen in the 3rd quarter valued at about $61,000. Headlands Technologies LLC bought a new position in shares of Repligen during the 3rd quarter worth approximately $75,000. Nisa Investment Advisors LLC boosted its stake in shares of Repligen by 67.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 533 shares of the biotechnology company’s stock worth $85,000 after buying an additional 215 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Repligen in the third quarter valued at approximately $95,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on RGEN. KeyCorp lifted their price target on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Stifel Nicolaus boosted their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Finally, JPMorgan Chase & Co. reduced their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $197.75.

Insider Transactions at Repligen

In related news, VP Ralf Kuriyel sold 3,517 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, VP Ralf Kuriyel sold 3,517 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the transaction, the vice president now owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares in the company, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. Insiders sold 25,597 shares of company stock valued at $5,039,532 over the last three months. Company insiders own 1.20% of the company’s stock.

Repligen Price Performance

NASDAQ RGEN opened at $165.50 on Thursday. The company has a quick ratio of 5.24, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. The company has a market cap of $9.25 billion, a PE ratio of 662.00, a price-to-earnings-growth ratio of 5.58 and a beta of 1.03. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The firm’s 50-day simple moving average is $179.23 and its two-hundred day simple moving average is $174.56.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter in the previous year, the company posted $0.64 earnings per share. The business’s quarterly revenue was down 17.1% compared to the same quarter last year. Research analysts predict that Repligen Co. will post 1.46 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.